Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Xeris Biopharma Holdings, Inc. Nasdaq

Equities

XERS

US98422L1070

Pharmaceuticals

Business Summary

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Number of employees: 377

Sales per Business

USD in Million2022Weight2023Weight Delta
Gvoke, Keveyis and Recorlev
93.6 %
109 99.1 % 153 93.6 % +40.36%
Royalty, Contract and Other
6.4 %
1 0.9 % 11 6.4 % +971.07%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
110 100.0 % 164 100.0 % +48.68%

Managers

Managers TitleAgeSince
Steven Prestrelski FOU
 Founder 60 31/12/04
Paul Edick CEO
 Chief Executive Officer 67 04/10/21
Steven Pieper DFI
 Director of Finance/CFO 47 31/12/20
John Shannon PSD
 President 62 04/10/21
Ken Johnson CTO
 Chief Tech/Sci/R&D Officer 61 30/09/21
Allison Wey IRC
 Investor Relations Contact - -
Kevin McCulloch PRN
 Corporate Officer/Principal - 30/09/18
Beth Hecht LAW
 General Counsel 60 30/09/21

Members of the board

Members of the board TitleAgeSince
John Johnson BRD
 Director/Board Member 66 04/10/21
Jeffrey Sherman BRD
 Director/Board Member 69 04/10/21
Marla Persky BRD
 Director/Board Member 68 04/10/21
Paul Edick CEO
 Chief Executive Officer 67 04/10/21
Garheng Kong BRD
 Director/Board Member 49 30/09/21
John Schmid BRD
 Director/Board Member 60 04/10/21
Barbara-Jean Bormann-Kennedy BRD
 Director/Board Member 65 04/10/21
Dawn Halkuff BRD
 Director/Board Member 53 04/10/21
Ricki Fairley BRD
 Director/Board Member 67 26/03/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 148,253,615 142,712,322 ( 96.26 %) 0 96.26 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
6.827 %
9,589,034 6.827 % 21 M $
Vanguard Fiduciary Trust Co.
5.045 %
7,086,345 5.045 % 16 M $
Stonepine Capital Management LLC
4.227 %
5,937,000 4.227 % 13 M $
Caxton Corp.
4.017 %
5,641,920 4.017 % 12 M $
MPM BioImpact, Inc
2.739 %
3,847,232 2.739 % 9 M $
Paul Edick
2.721 %
3,821,494 2.721 % 8 M $
Geode Capital Management LLC
2.059 %
2,892,077 2.059 % 6 M $
Rosalind Advisors, Inc.
2.008 %
2,820,170 2.008 % 6 M $
STATE STREET CORPORATION
1.940 %
2,724,126 1.940 % 6 M $
Steven Pieper
1.158 %
1,626,912 1.158 % 4 M $

Company contact information

Xeris Biopharma Holdings, Inc.

1375 West Fulton Street Suite 1300

60607, Chicago

+

http://www.xerispharma.com
address Xeris Biopharma Holdings, Inc.(XERS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. XERS Stock
  4. XERS Stock
  5. Company Xeris Biopharma Holdings, Inc.